HERITX INC
1217 Wilshire Blvd 3390, Santa Monica, CA 90403 www.heritx.org

---

Organizations Filed Purposes: HeritX, Inc. is a nonprofit corporation formed with the stated mission of preventing inherited cancer by raising awareness and providing resources and expertise to promote research and innovation for development of therapies for the prevention of inherited cancers. HeritX's strategy is to convene leading experts worldwide in the field of cancer research, facilitate the exchange of ideas and collaboration, and coordinate, design, direct, and fund research efforts to accelerate the achievement of cancer prevention.

HeritX is a nonprofit corporation formed with the stated mission of preventing inherited cancer.

The HeritX mission is to prevent inherited cancers. The first program, launched in 2015, is the Global HeritX Initiative to Prevent Inherited BRCA Cancers (The HeritX Initiative), which was publicly launched in November 2015 with a Banbury Conference at Cold Spring Harbor Laboratory. This meeting resulted in the first research and development (R&D) roadmap to prevent inherited BRCA cancer. Following the conference, HeritX connected with more than 200 research groups to identify ideas to prevent BRCA cancers, and selected the most promising ideas for HeritX to support. HeritX's work includes enabling ongoing projects, initiated in 2017 and 2018. One of these projects, which involves an international collaborative cancer prevention vaccine project at the Netherlands Cancer Institute, Dana-Farber Cancer Institute, Johns Hopkins University and ISA Pharmaceuticals. In addition, HeritX released a global request for new BRCA cancer prevention research proposals in 2018 and received new research proposals. Final selection of new projects for funding will happen in 2019 following external peer review. Information about HeritX's grant program and grant selection process can be found at https://www.heritx.org/faq/.

Conferences, meetings, education and community engagement programs: HeritX continued to expand the Prevention Advocacy Network ("PAN") in 2018. The goal of the PAN is to bring the voice of the BRCA community to the research and development process, including decisions on research direction and priorities. PAN forums in 2018 were held in South Florida, in Kansas City in collaboration with Menorah Medical Center, and in Montreal in connection with the International Symposium on Hereditary Breast and Ovarian Cancer. The PAN is a community engagement platform that ensures that prevention research focuses on a future preventive therapy that will meet the needs of the community - not only in terms of the level of risk reduction but also in terms of convenience and side effects. Today, surgery is the only option for preventing BRCA cancers. Many women choose this route, removing breasts and ovaries and enduring the consequences of these surgeries. The PAN was used as a mechanism to provide patient input to the investigators in the area of inherited cancer prevention research. Through the PAN, families voice their hopes for a future without surgery. In addition to the PAN, HeritX extended its community outreach and education initiatives through multiple speaking engagements, community forums and educational programs. In 2018, HeritX conducted a panel discussion and forum on BRCA prevention research at the International Symposium on Hereditary Breast and Ovarian Cancer in Montreal, Canada, which generated new interest in the HeritX mission and research programs. In addition, HeritX collaborated with other organizations on educational programs about BRCA cancer, HeritX's mission, and BRCA cancer prevention research endeavors including with One in Forty, Rotary International, and Kehilat Israel. HeritX also hosted educational forums in Los Angeles and on Long Island.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/201941239349300239_public.xml